1naresh

Array
(
    [urn:ac.highwire.org:guest:identity] => Array
        (
            [runtime-id] => urn:ac.highwire.org:guest:identity
            [type] => guest
            [service-id] => ajnr-ac.highwire.org
            [access-type] => Controlled
            [privilege] => Array
                (
                    [urn:ac.highwire.org:guest:privilege] => Array
                        (
                            [runtime-id] => urn:ac.highwire.org:guest:privilege
                            [type] => privilege-set
                            [privilege-set] => GUEST
                        )

                )

            [credentials] => Array
                (
                    [method] => guest
                )

        )

)
1nareshArray
(
    [urn:ac.highwire.org:guest:identity] => Array
        (
            [runtime-id] => urn:ac.highwire.org:guest:identity
            [type] => guest
            [service-id] => ajnr-ac.highwire.org
            [access-type] => Controlled
            [privilege] => Array
                (
                    [urn:ac.highwire.org:guest:privilege] => Array
                        (
                            [runtime-id] => urn:ac.highwire.org:guest:privilege
                            [type] => privilege-set
                            [privilege-set] => GUEST
                        )

                )

            [credentials] => Array
                (
                    [method] => guest
                )

        )

)

Table 2: Overall survival stratified by progression status at week 16
Sequence Progression by Week 16? Progression by Week 16? (R vs NR-NP)
No Yes R NR-NP P
N (%), Median OS (days) (95% CI) N (%), Median OS (days) (95% CI) N (%), Median OS (days) (95% CI) N (%), Median OS (days) (95% CI) N (%), Median OS (days) (95% CI)
2D 36 (63%) 21 (37%) 16 (28%) 20 (35%) 21 (37%)
448 (321–660) 212 (170–268) 437 (319–971) 451 (232–687) 212 (170–268)
P < .0001^{^a} (n = 57) P = .73: R vs NR-NP
dT1 31 (54%) 26 (46%) 23 (40%) 8 (14%) 26 (46%)
434 (319–676) 221.5 (196–309) 448 (319–687) 362.5 (127, –) 221.5 (196–309)
P = .006^{^a} (n = 57) P = .61: R vs NR-NP
Note:— – indicates those that were still alive at the end of study (i.e., no upper bound); N, number of patients; R, responder; NR-NP, non-responder/non-progressor; P, progressor.
↵a Significant.